bz371a
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 16, 2022 (NCT05332340)
Timeline
Indications
Mechanism of action
- Nitric-oxide synthase, brainACTIVATOR
NOS1 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06651541 | Phase 2 | Jul 1, 2025 | Biozeus Biopharmaceutical S.A. |
| NCT06116045 | Phase 2 | Apr 1, 2024 | Biozeus Biopharmaceutical S.A. |
| NCT05558007 | Phase 2 | Mar 31, 2023 | Biozeus Biopharmaceutical S.A. |
| NCT05332340 | Phase 1 | Nov 16, 2022 | Azidus, Biozeus Biopharmaceutical S.A. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biozeus Biopharmaceutical S.A. | For profit | 4 | 4 | 2 | 2022 |
| Azidus | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1